<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Yunnan Baiyao (White Medicine from Yunnan, YNB) is a Chinese herbal medicinal powder used to stop <z:mp ids='MP_0001914'>bleeding</z:mp> and improve circulation in traumatic injuries </plain></SENT>
<SENT sid="1" pm="."><plain>We describe the use of YNB in adolescents with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> as an adjunct to uncontrolled <z:mp ids='MP_0001914'>bleeding</z:mp> in the palliative care setting </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Through a retrospective chart review of <z:hpo ids='HP_0000001'>all</z:hpo> patients receiving integrative medicine consultations at the Integrative Therapies Program at Columbia University from January 1, 2007 to January 31, 2012, we describe the outcome of patients treated with YNB for management of uncontrolled <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Four patients were identified who received topical YNB for uncontrolled <z:mp ids='MP_0001914'>bleeding</z:mp>; patients included two males and two females with diagnoses of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> (n = 3) and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 1) </plain></SENT>
<SENT sid="4" pm="."><plain>Mean age was 15.5 years (range 15-17) </plain></SENT>
<SENT sid="5" pm="."><plain>Fifty percent had life-threatening <z:mp ids='MP_0001914'>bleeding</z:mp> from the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> site and 50 % experienced uncontrollable <z:hpo ids='HP_0000421'>epistaxis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received preceding therapy with packed red blood cells and platelet transfusions, topical thrombin, and oral <z:chebi fb="0" ids="16586">aminocaproic acid</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Two patients used YNB in the inpatient setting, and <z:hpo ids='HP_0000001'>all</z:hpo> four patients used YNB as outpatients </plain></SENT>
<SENT sid="8" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> patients, <z:mp ids='MP_0001914'>bleeding</z:mp> control improved with the addition of YNB to conventional hemostatic interventions </plain></SENT>
<SENT sid="9" pm="."><plain>Two patients using YNB in their home reported control of <z:mp ids='MP_0001914'>bleeding</z:mp> episodes </plain></SENT>
<SENT sid="10" pm="."><plain>There were no adverse events reported </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: YNB may be an efficacious agent for uncontrolled <z:mp ids='MP_0001914'>bleeding</z:mp> in conjunction with conventional hemostatic agents in adolescents with <z:e sem="disease" ids="C0877373" disease_type="Neoplastic Process" abbrv="">advanced cancer</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>It is well accepted by patients </plain></SENT>
<SENT sid="13" pm="."><plain>YNB may be especially valuable in the outpatient setting to prevent the recurrence of <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
</text></document>